Somi Igbene, PhD,  science writer—

Quantitative sensory testing (QST), a tool for monitoring nerve function, may help to detect problems in small nerve fibers in people with late-onset familial amyloid polyneuropathy (FAP) before symptoms start, a small study suggested. Adults with disease-causing mutations for late-onset FAP but no disease symptoms had more abnormal responses…

Long-term treatment with Tegsedi (inotersen) reduced pain and improved physical functioning and health-related quality of life in patients with familial amyloid polyneuropathy (FAP). That’s according to an analysis of data from the Phase 3 NEURO-TTR trial (NCT01737398) and its open-label extension (OLE) study (NCT02175004).